This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
Age ≥18 years;
Histologically confirmed nasopharyngeal carcinoma;
Expected survival time ≥12 weeks;
ECOG performance status: 0-1;
Histologically confirmed keratinizing squamous cell carcinoma (WHO I)；
Distant metastasis detected by pre-treatment clinical or imaging examinations;
History of allergy to any component of monoclonal antibodies, tislelizumab, or capecitabine;
Autoimmune-related hypothyroidism on stable thyroid hormone replacement therapy;